Search

Your search keyword '"Maruyama, Dai"' showing total 12 results
Start Over Author "Maruyama, Dai" Language english Journal annals of hematology
12 results on '"Maruyama, Dai"'

1. Secondary central nervous system involvement in patients with diffuse large B-cell lymphoma treated with rituximab combined CHOP therapy – a supplementary analysis of JCOG0601

Author

Shimada, Kazuyuki, Ohmachi, Ken, Machida, Ryunosuke, Ota, Shuichi, Itamura, Hidekazu, Tsujimura, Hideki, Takayama, Nobuyuki, Shimada, Takaki, Kurosawa, Mitsutoshi, Tabayashi, Takayuki, Shimoyama, Tatsu, Ohshima, Koichi, Miyazaki, Kana, Maruyama, Dai, Kinoshita, Tomohiro, Ando, Kiyoshi, Hotta, Tomomitsu, Tsukasaki, Kunihiro, and Nagai, Hirokazu

Published
2024
Full Text
View/download PDF

6. Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma

Author

Maruyama, Dai, Tsukasaki, Kunihiro, Uchida, Toshiki, Maeda, Yoshinobu, Shibayama, Hirohiko, Nagai, Hirokazu, Kurosawa, Mitsutoshi, Suehiro, Yoko, Hatake, Kiyohiko, Ando, Kiyoshi, Yoshida, Isao, Hidaka, Michihiro, Murayama, Tohru, Okitsu, Yoko, Tsukamoto, Norifumi, Taniwaki, Masafumi, Suzumiya, Junji, Tamura, Kazuo, Yamauchi, Takahiro, Ueda, Ryuzo, and Tobinai, Kensei

Published
2019
Full Text
View/download PDF

7. Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment

Author

Kitahara, Hideaki, Maruyama, Dai, Maeshima, Akiko Miyagi, Makita, Shinichi, Miyamoto, Ken-ichi, Fukuhara, Suguru, Munakata, Wataru, Suzuki, Tatsuya, Kobayashi, Yukio, Tajima, Kinuko, Terauchi, Takashi, Kurihara, Hiroaki, Taniguchi, Hirokazu, Komatsu, Norio, and Tobinai, Kensei

Published
2017
Full Text
View/download PDF

9. Correction to: Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma

Author

Maruyama, Dai, Tsukasaki, Kunihiro, Uchida, Toshiki, Maeda, Yoshinobu, Shibayama, Hirohiko, Nagai, Hirokazu, Kurosawa, Mitsutoshi, Suehiro, Yoko, Hatake, Kiyohiko, Ando, Kiyoshi, Yoshida, Isao, Hidaka, Michihiro, Murayama, Tohru, Okitsu, Yoko, Tsukamoto, Norifumi, Taniwaki, Masafumi, Suzumiya, Junji, Tamura, Kazuo, Yamauchi, Takahiro, Ueda, Ryuzo, and Tobinai, Kensei

Published
2018
Full Text
View/download PDF

12. Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy.

Author

Maeshima, Akiko Miyagi, Taniguchi, Hirokazu, Fujino, Takahiro, Saito, Yo, Ito, Yuta, Hatta, Shunsuke, Yuda, Sayako, Makita, Shinichi, Fukuhara, Suguru, Munakata, Wataru, Suzuki, Tatsuya, Maruyama, Dai, and Izutsu, Koji

Subjects
NON-Hodgkin's lymphoma, DIFFUSE large B-cell lymphomas
Abstract

CD20− change after rituximab-containing therapy is considered one of the main reasons of rituximab resistance of B-cell non-Hodgkin lymphomas (B-NHLs). However, the clinicopathological characteristics of B-NHL with CD20− change are not entirely understood. In this study, 252 B-NHL patients who were CD20+ at initial diagnosis, whose diseases relapsed or were refractory after rituximab-containing therapy, and who were re-biopsied between 2000 and 2018, were included. The median number of rituximab administration was 11 (range, 1–48). Completely negative (cCD20−) and partially negative (pCD20−) change of CD20 was observed in 49 (20%) and 16 (6%) cases, respectively. Among cCD20− and pCD20− cases, 74% and 62% of the cases changed to CD20− at the second relapse or later, respectively. Overall survival was significantly shorter in cCD20− follicular lymphoma (FL) cases than in CD20+ FL cases. Seven histopathological patterns, such as CD20− change without histological change, histological transformation (HT) to CD20− diffuse large B-cell lymphoma, and proliferation of plasmablastic/plasmacytoid tumor cells, were associated with CD20− change. HT occurred more frequently in FLs with CD20− change than in FLs continuously expressing CD20 (P < 0.0001), regardless of the timing of HT. Nine out of 25 cases (36%) showed regain or heterogeneous regain of CD20 expression. In conclusion, 20% and 6% of the 252 B-NHL cases show cCD20− and pCD20− changes with 7 histological patterns after rituximab-containing therapy. Because changes in morphology and CD20 expression after rituximab-containing therapy vary, and recovery of CD20 expression is not rare, careful follow-up and re-biopsy in B-NHL patients are recommended. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results